Biotechnology Companies By Roe

Return On Equity
Return On EquityEfficiencyMarket RiskExp Return
1HALO Halozyme Therapeutics
2.22
 0.01 
 2.41 
 0.02 
2AMGN Amgen Inc
1.36
 0.02 
 1.39 
 0.03 
3ROIV Roivant Sciences
1.06
 0.11 
 2.32 
 0.26 
4NTII Neurobiological Technologies
1.0
 0.00 
 0.00 
 0.00 
5OCUP Ocuphire Pharma
0.93
(0.06)
 2.89 
(0.17)
6VYGR Voyager Therapeutics
0.9
 0.06 
 4.65 
 0.28 
7PLX Protalix Biotherapeutics
0.79
 0.06 
 3.14 
 0.18 
8ZYME Zymeworks Common Stock
0.68
 0.16 
 3.00 
 0.48 
9MDXG MiMedx Group
0.62
 0.03 
 2.62 
 0.07 
10XCUR Exicure
0.56
 0.15 
 8.53 
 1.30 
11IXHL Incannex Healthcare
0.52
 0.01 
 11.68 
 0.15 
12ARCT Arcturus Therapeutics Holdings
0.47
 0.21 
 4.34 
 0.89 
13ALKS Alkermes Plc
0.46
 0.08 
 2.89 
 0.24 
14MOR MorphoSys AG ADR
0.42
 0.20 
 9.42 
 1.86 
15PROC Procaps Group SA
0.37
 0.00 
 5.04 
 0.00 
16PROCW Procaps Group SA
0.37
 0.14 
 149.05 
 20.41 
17MEIP MEI Pharma
0.37
(0.24)
 2.84 
(0.67)
18ABBV AbbVie Inc
0.35
 0.38 
 0.89 
 0.34 
19MGNX MacroGenics
0.31
 0.35 
 3.82 
 1.33 
20GILD Gilead Sciences
0.26
(0.06)
 1.83 
(0.11)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income. For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.